miR-146a rs291064 Identified as Risk Factor for Gastric Cancer
the Cancer Therapy Advisor take:
Investigators found an association between miR-146a rs291064 and risk of gastric cancer (GC) development, according to an article published online in the journal European Journal of Cancer Care.
The authors performed a meta-analysis using PubMed and China National Knowledge Infrastructure searches in order to find relevant studies published before July 2014.
In total, seven case-control studies were chosen for the data analysis, including 3,283 cases and 4,535 controls.
Results showed a significant correlation between the genetic polymorphism miR-146a rs291064 and risk of GC under all genetic models (CC vs. GG, OR=0.76, 95% CI: 0.66, 0.87; CC vs. GC+GG, OR=0.84, 95% CI: 0.71, 0.99; CC+GC vs. GG, OR=0.82, 95% CI: 0.73, 0.91).
Furthermore, the authors conducted subgroup analysis by ethnicity and identified an association in Asian that was determined to be statistically significant.
Investigators found an association between miR-146a rs291064 and risk of gastric cancer development.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Considerations for Relapsed Myeloma Should Match Patient, Disease, and Therapy
- Triclosan and Cancer Risk: Is There a Link?
- Research Advances for Mutant KRAS-Driven Lung Adenocarcinoma
- Chemotherapy May Improve Survival Outcomes in High-Risk Soft-Tissue Sarcoma
- Aggressive Follow-Up Imaging in Breast Cancer Is Geography-Specific
- FDA Approves Ivosidenib for IDH1-Mutated Relapsed/Refractory Acute Myeloid Leukemia
- Clinical Stage at First Response May Predict Outcomes in Chronic Lymphocytic Leukemia
- Exercise and Cancer
- Increased Body Mass Index May Be Predictive of Recurrence, Progression in Bladder Cancer
- Aspirin, Non-Aspirin NSAID-Use May Improve Survival Outcomes in Ovarian Cancer